HDL Soars, LDL Drops With Novel CETP Inhibitor Anacetrapib
Major Finding: At 24 weeks, once-daily anacetrapib increased HDL cholesterol levels from 40 mg/dL to 101 mg/dL and decreased LDL levels from 81 mg/dL to 45 mg/dL, both highly significant differences from placebo.
Data Source: DEFINE, a phase III trial in 1,623 patients with or at high risk for coronary heart disease.
Disclosures: DEFINE was supported by Merck Research Laboratories. Dr. Cannon and his coauthors report financial relationships with several pharmaceutical firms including Merck. Dr. Cannon also serves as an advisor and holds equity in Automedics Medical Systems.
FROM THE ANNUAL SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION
Follow-up from REVEAL is planned in 4 years, which means that barring any new safety signals, anacetrapib would be submitted for approval in about 2015, Dr. Cannon said in an interview.
Results of DEFINE were published online simultaneously with Dr. Cannon’s presentation (N. Engl. J. Med. 2010 [doi:10.1056/NEJMoa1009744]).
DEFINE was supported by Merck Research Laboratories. Dr. Cannon and his co-authors report financial relationships with several pharmaceutical firms including Merck. Dr. Cannon also serves as an advisor and holds equity in Automedics Medical Systems.
